Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 212

Aimmune’s peanut allergy drug meets main goal

U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Read More »

FDA expands use of Amgen’s blockbuster drug

Amgen Inc. said the U.S. FDA approved its drug Xgeva to prevent fractures in patients with multiple myeloma.

Read More »

Roche scores cancer drug approvals in Europe, U.S.

Swiss drugmaker Roche won approvals for two cancer drugs in Europe and the United States, shoring up its position in new medicines as it braces for falling sales of older products.

Read More »

Germany’s Merck in fresh bid to enter U.S. MS pill market

Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.

Read More »

Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe

Daiichi Sankyo Europe GmbH informed Nektar Therapeutics that it was terminating a collaboration and licensing deal, which becomes effective Feb. 4, 2018. All rights and licenses that Daiichi acquired in the deal will revert to Nektar.

Read More »

Troubled Otonomy Cuts Jobs

Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.

Read More »

Europe’s HIV epidemic growing at alarming rate, WHO warns

The number of people newly diagnosed with HIV in Europe reached its highest level in 2016 since records began, showing the region’s epidemic growing “at an alarming pace,” health officials said.

Read More »

Trump declares opioid epidemic a public health emergency; crisis could spread to Europe, experts say

As U.S. President Donald Trump declared the opioid crisis a public health emergency, Europe should heed the threat from opioids responsible for America’s deadliest drug epidemic in decades as both regions have seen rises in prescription rates of such medicines, which can be a gateway to dangerous derivatives according to experts.

Read More »

Drugmakers’ hopes for gene therapy rise despite tiny sales in Europe

The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe.

Read More »

EU tests limits of drug pricing freedom in landmark probe

The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

Read More »

Google backs new European biotech drug fund

Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.

Read More »

European Commission Approves Pfizer’s Trumenba to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

Pfizer Inc. announced that the European Commission approved Trumenba (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.

Read More »

UK biotech boasts Europe’s best pipeline as Brexit threat looms

Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.

Read More »

In Europe, U.S., modern AIDS drugs add extra 10 years of life expectancy

Life expectancy for young HIV-positive adults has risen by 10 years in the United States and Europe.

Read More »

Gilead hepatitis C drug patent faces European challenge

International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences’ hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

Read More »

Diabetes study: Many common genes at play

A study examining genes of more than 120,000 people from Europe, Asia, Africa and the Americas has offered the clearest picture yet of those that drive type 2 diabetes.

Read More »

Sanofi says LixiLan diabetes drug trials meet targets

France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.

Read More »

Zika virus may spread to Europe in coming months, WHO warns

The Zika virus may spread into Europe as the weather gets warmer, although the risk is low, health officials said.

Read More »

UBS, MPM team up on $471 million cancer fund to speed drug development

A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs.

Read More »

Europe is malaria free, 214 million cases in rest of world in 2015: WHO

(Thomson Reuters Foundation) – Europe has become the world’s first region to wipe out malaria, with zero cases reported last year, the World Health Organization (WHO) said on Wednesday. The number of indigenous malaria cases dropped to zero in 2015 from 90,712 in 1995, and the last cases were reported in Tajikistan in 2014, it […]

Read More »

Page 1 of 212

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation